Detalles de la búsqueda
1.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet
; 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38705160
2.
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
Ann Hematol
; 2024 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459156
3.
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.
Ann Hematol
; 102(10): 2791-2801, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552322
4.
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.
Br J Haematol
; 184(4): 616-624, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30095158
5.
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.
Biol Blood Marrow Transplant
; 24(6): 1172-1179, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29605716
6.
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.
Blood
; 128(8): 1112-20, 2016 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27418643
7.
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Lancet
; 388(10044): 565-75, 2016 Aug 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27313086
8.
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Blood
; 126(5): 604-11, 2015 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26022239
9.
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Lancet Oncol
; 16(9): 1111-1122, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26256760
10.
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.
Blood
; 119(19): 4383-6, 2012 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22374696
11.
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
J Clin Oncol
; 42(5): 550-561, 2024 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38096461
12.
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Leukemia
; 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38678093
13.
Impact of age on genetics and treatment efficacy in follicular lymphoma.
Haematologica
; 103(8): e364-e367, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545350
14.
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Leukemia
; 37(9): 1887-1894, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37495776
15.
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
J Clin Oncol
; 41(3): 479-484, 2023 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36469833
16.
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Blood
; 115(16): 3215-23, 2010 Apr 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-20032498
17.
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Blood Adv
; 6(18): 5285-5294, 2022 09 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35439293
18.
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Blood Adv
; 6(13): 3911-3920, 2022 07 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35537101
19.
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
Blood
; 113(21): 5250-3, 2009 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-19279329
20.
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Blood
; 113(17): 3903-10, 2009 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-19131552